Navigation Links
MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/14/2008

lion in the first six months of 2007.

Net loss per share applicable to common stockholders during the second quarter of 2008 was ($0.07), compared to a net loss per share of ($0.26) in the prior quarter, and a net loss per share of ($0.21) in the comparable quarter of last year. Net loss per share applicable to common stockholders during the first half of 2008 was ($0.32), down from a net loss per share of ($0.57) in the first half of 2007.

"Having concluded our strategic review process over the second quarter, we are now working to close the Equity Group transaction and prepare for the potential commercial launch of MOXATAG," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook. "The entire MiddleBrook team is excited to now have the opportunity to introduce once-daily MOXATAG, our first proprietary PULSYS product, into the marketplace by as early as the first half of next year."

OPERATIONAL HIGHLIGHTS

Strategic Review Process Concluded with Agreement for $100 Million Equity Investment

On July 1, 2008, MiddleBrook announced that it had concluded its previously announced review of strategic alternatives with an agreement for a $100 million equity investment in the Company by EGI-MBRK L.L.C. (EGI), an affiliate of Equity Group Investments, L.L.C. On July 1, 2008, MiddleBrook entered into a securities purchase agreement with EGI for the sale of 30,303,030 shares of MiddleBrook common stock at $3.30 per share and a five- year warrant to purchase a total of 12,121,212 shares of common stock at an exercise price of $3.90 per share.

As part of the agreement with EGI and as previously announced, a new, commercially-focused executive management team will be appointed. Proceeds from the transaction are expected to allow the Company to move forward with the commercial launch of MOXATAG(TM) and to continue the development of its clinical pipeline.

The issuance of the new shares and the warrant is subject to approval
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
2. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
5. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
6. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
7. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
8. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
9. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
10. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
11. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... The Mesothelioma ... part of its support program. This discussion series is part of the Meso ... services to those affected by mesothelioma. , The six week discussion series is ...
(Date:6/29/2015)... , ... June 29, 2015 , ... Displays and ... imprinted accessories, is offering discounted pricing on all purchases that include branding. Enter price ... a brand is the logo. The website, packaging and promotional materials, all should integrate ...
(Date:6/29/2015)... Wethersfield, CT (PRWEB) , ... June 29, 2015 ... ... their centers recognized by the independent auditor of customer service for the 40-center ... of more than 1,100 skilled nursing centers in the United States in one ...
(Date:6/29/2015)... ... June 29, 2015 , ... Assurex Health, ... with certain neuropsychiatric and chronic pain conditions, has announced appointments to three key ... include: Peter Donato, Senior Vice President, Chief Financial Officer; Craig S. Lewis, Senior ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... Conference shows that fewer than 10 percent of U.S. state and local governments ... have set an implementation deadline for NG9-1-1. , “Mobile phones have surpassed ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Provides Support for Patients and Families 2Health News:Mesothelioma Organization Provides Support for Patients and Families 3Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4
... say the report from China is no cause for ... have identified a probable case of human-to-human transmission of ... to the idea that there,s a genetic component to ... study reported. , "This suggests that there,s some genetic ...
... Albemarle,Corporation (NYSE: ALB ) will hold its quarterly conference ... at 8:00am ET., This call is being webcast by ... http://www.albemarle.com in the Investor,Information section., ... Dial In # 800-591-6942 International ...
... NEW YORK, April 7, 2008 American Media, ... at its corporate website certain,information currently required to ... lenders under its amended Senior Secured Credit Agreement., ... monthly,circulation of certain key magazine titles during the ...
... 2008 DURECT,Corporation (Nasdaq: DRRX ) announced ... to return the rights to CHRONOGESIC(R) licensed from,DURECT ... a product,candidate consisting of a sufentanil containing implantable ... As a result, the,Development, Commercialization and Supply License ...
... University School of Medicine in St. Louis report that ... operative procedure they achieved a significant improvement in the ... , Reporting in the April issue of the Journal ... enhancement to the Cox-Maze procedure, a surgical procedure that ...
... to Help Provide Tetanus Vaccines to ... in Developing Countries, CINCINNATI, April 7, 2008 ... decades and today, the world,s leading,diaper brand kicked off ... to UNICEF to provide life-saving tetanus,vaccines to women of ...
Cached Medicine News:Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2Health News:DURECT Provides Update on CHRONOGESIC(R) Research Program 2Health News:Surgeons announce advance in atrial fibrillation surgery 2Health News:Surgeons announce advance in atrial fibrillation surgery 3Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 2Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 3Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 4Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 5
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: